CTRI/2024/06/068939
Not yet recruiting
未知
A Prospective Interventional Open label Single-centre Single arm Study to Evaluate the Efficacy and Safety of CoQ10 Capsules in Subject suffering with Oligospermia - NI
M/s Synthite Industries Private Limited0 sites0 target enrollmentTBD
ConditionsHealth Condition 1: N461- Oligospermia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: N461- Oligospermia
- Sponsor
- M/s Synthite Industries Private Limited
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1 Male participants aged 18 to 50 years
- •2 Diagnosis of oligospermia, confirmed by semen analysis showing a sperm concentration of less than 15 million sperm per milliliter or through medical history of the subjects
- •3 Willingness to provide informed consent to participate in the study
- •4 Ability to comply with the study protocol including attending study visits and completing study\-related assessments.
- •5 Stable sexual partner or intention to engage in heterosexual intercourse for the duration of the study
- •6 Willingness to refrain from using other fertility treatments or supplements during the study period
- •7 Adequate understanding of the study procedures and willingness to follow the investigators instructions
Exclusion Criteria
- •1\. History and drug alcohol abuse smoking
- •2\. BMI greater than 30 kg per m2
- •3\. History of cancer chemotherapy
- •4\. History of significant medical conditions that could affect fertility or interfere with study participation including severe cardiovascular disease uncontrolled hypertension renal failure liver disease or malignancy
- •5\. Contraindication for the use of CoQ10
- •6\. Genital disease (cryptorchidism current genital inflammation or varicocele)
- •7\. Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS) related illness and or known history of Hepatitis B virus (HBV) defined by presence of hepatitis B surface antigen (HBsAg) and or known history of Hepatitis C virus (HCV) defined by presence of hepatitis C antibody (HCVAb)
- •8\. Genital trauma or surgery to the reproductive system
- •9\. Hepatobiliary disease
- •10\. Significant renal insufficiency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
To check the Efficacy and Safety of Gymne Mag D Capsules in patients with Type 2 Diabetes MellitusCTRI/2024/06/068889M/s Synthite Industries Private Limited
Not yet recruiting
Not Applicable
To see the Efficacy and Safety of ProPlus Capsules in patients with Benign Prostatic Hyperplasia (BPH)CTRI/2024/06/068991M/s Synthite Industries Private Limited
Not yet recruiting
Not Applicable
To check the Efficacy and Safety of Ashwagandha DSTR Capsule in patients with Moderate Stress Mild Anxiety Depression Low Stamina and StrengthHealth Condition 1: F430- Acute stress reactionCTRI/2024/06/069402M/s Synthite Industries Private Limited
Active, not recruiting
Phase 1
Prospective, interventional, open-label single center pilot study to evaluate FERInject Efficacy in 20 maintenance kidney transplant recipients.This study is aimed at kidney transplant recipient with chronic kidney disease, iron deficiency and anemia.MedDRA version: 21.1Level: LLTClassification code 10050308Term: Iron replacementSystem Organ Class: 100000004865Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2020-002956-20-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE20
Completed
Not Applicable
efficacy and safety ofSilverNovaTM Skin Cream in Post aesthetic skin procedures subjects.Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecifiedCTRI/2022/07/043752Viridis BioPharma Pvt Ltd60